https://www.insidermonkey.com/blog/nektar-therapeutics-nasdaqnktr-q4-2023-earnings-call-transcript-1269284/
Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript - Insider Monkey
Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.22 EPS, expectations were $-0.2.
earnings call transcriptnektar therapeuticsq4 2023nasdaqnktr
https://www.fool.com/investing/2025/07/03/why-nektar-therapeutics-stock-dived-by-3-today/
Why Nektar Therapeutics Stock Dived by 3% Today | The Motley Fool
Jul 3, 2025 - Why Nektar Therapeutics Stock Dived by 3% Today
nektar therapeuticsstockdived
https://www.biospace.com/press-releases/nektar-therapeutics-to-participate-in-two-investor-conferences-in-september-2025
Nektar Therapeutics to Participate in Two Investor Conferences in September 2025 - BioSpace
nektar therapeuticsto participatein twoinvestor conferencesseptember 2025
https://finviz.com/news/157391/nektar-therapeutics-to-participate-in-two-investor-conferences-in-september
Nektar Therapeutics to Participate in Two Investor Conferences in September
Stock screener for investors and traders, financial visualizations.
nektar therapeuticsto participatein twoinvestor conferencesseptember
https://www.fxempire.com/stocks/nktr/history
Nektar Therapeutics (NKTR) Stock Price History | FXEmpire
Get in-depth historical insights into (NKTR) Nektar Therapeutics's stock performance. With data on prices, highs, lows, and change percentages, our page allows...
stock price historynektar therapeuticsnktr
https://www.prnewswire.com/news-releases/pre-market-equity-watch-on-biotechnology----infinity-pharma-nektar-therapeutics-aralez-pharma-and-bind-therapeutics-584094681.html
Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma,...
/PRNewswire/ -- On Wednesday, June 22, 2016, the NASDAQ Composite ended the trading session at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged...
pre marketwatch onnektar therapeuticsequity
https://www.nasdaq.com/market-activity/stocks/nktr/price-earnings-peg-ratios
Nektar Therapeutics Common Stock (NKTR) Price/Earnings & PEG Ratios | Nasdaq
Get updated information on Nektar Therapeutics Common Stock (NKTR) Price/Earnings Ratio (or PE Ratio) and PEG ratio for stock evaluations with Nasdaq.
nektar therapeuticscommon stockprice earningspeg ratiosnktr
https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-pricing-of-upsized-325-million-public-offering-302749508.html
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of...
nektar therapeuticsannouncespricing325million
https://www.nasdaq.com/market-activity/stocks/nktr
Nektar Therapeutics Common Stock (NKTR) Stock Price, Quote, News & History | Nasdaq
Discover real-time Nektar Therapeutics Common Stock (NKTR) stock prices, quotes, historical data, news, and Insights for informed trading and investment...
nektar therapeuticscommon stockprice quotenews historynktr
https://www.annualreports.com/Company/nektar-therapeutics
Nektar Therapeutics - AnnualReports.com
nektar therapeutics
https://www.biospace.com/nektar-therapeutics-reports-second-quarter-2024-financial-results
Nektar Therapeutics Reports Second Quarter 2024 Financial Results - BioSpace
2024 financial resultsnektar therapeuticssecond quarterreports
https://www.biospace.com/nektar-therapeutics-ovarian-cancer-drug-benefits-women-in-study
Nektar Therapeutics Ovarian Cancer Drug Benefits Women in Study - BioSpace
nektar therapeuticsovarian cancerwomen indrugbenefits
https://www.fxempire.com/stocks/nktr/profile
NKTR: Nektar Therapeutics Company Profile & Statistics | FXEmpire
Dive into the Nektar Therapeutics (NKTR) company profile. Key financial ratios, comprehensive company statistics, and essential NKTR data, all in one place on...
nektar therapeuticscompany profilenktrstatistics
https://www.fool.com/quote/nasdaq/nktr/
Nektar Therapeutics - NKTR - Stock Price & News | The Motley Fool
nektar therapeuticsstock pricenktrnewsmotley
https://www.prnewswire.com/news-releases/nektar-therapeutics-to-webcast-conference-call-with-urothelial-cancer-specialist-for-analysts--investors-at-the-2019-asco-genitourinary-cancers-symposium-300793500.html
Nektar Therapeutics to Webcast Conference Call with Urothelial Cancer Specialist for Analysts &...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will webcast an analyst and investor conference call with a urothelial cancer...
nektar therapeuticsconference call
https://www.prnewswire.com/news-releases/nktr-investors-have-opportunity-to-lead-nektar-therapeutics-securities-fraud-lawsuit-302749572.html
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
/PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between...
nektar therapeuticssecurities fraudnktrinvestorsopportunity
https://finviz.com/quote?t=NKTR&ty=fc&ta=1&p=d
NKTR - Nektar Therapeutics Forecast, Target Price
NKTR - Nektar Therapeutics - Stock screener for investors and traders, financial visualizations.
nektar therapeuticsnktrforecasttargetprice
https://www.prnewswire.com/news-releases/nktr-upcoming-deadline-faruqi--faruqi-llp-reminds-nektar-therapeutics-nktr-investors-of-securities-class-action-deadline-on-may-5-2026-302738897.html
NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of...
nektar therapeuticsnktrupcomingdeadlinefaruqi
https://www.oanda.com/eu-ro/trading/shares/us/nektar-therapeutics
Nektar Therapeutics (NKTR) Trading | Shares / Shares CFDs | OANDA
Trade Nektar Therapeutics (NKTR) shares CFDs with OANDA. View live charts and current market interest for this stock.
nektar therapeuticsnktrtradingsharescfds
https://www.globenewswire.com/news-release/2024/04/24/2868445/0/en/Biolojic-Design-Announces-that-Nektar-Therapeutics-Has-Exercised-Its-License-Option-to-Develop-an-AI-Designed-Agonistic-Antibody-Targeting-TNFR2-for-the-Treatment-of-Autoimmune-Dis.html
Biolojic Design Announces that Nektar Therapeutics Has
Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology...
nektar therapeuticsdesignannounces
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/have-insiders-sold-nektar-therapeutics-shares-recently
Have Insiders Sold Nektar Therapeutics Shares Recently? - Simply Wall St News
simply wall stnektar therapeuticsinsiderssold
https://www.fool.com/investing/2021/11/05/why-nektar-therapeutics-stock-plunged-today/
Why Nektar Therapeutics Stock Plunged Today | The Motley Fool
Nov 5, 2021 - The company's Q3 revenue was lower than expected.
nektar therapeuticsstockplungedtodaymotley
https://www.prnewswire.com/news-releases/nktr-investors-have-opportunity-to-lead-nektar-therapeutics-securities-fraud-lawsuit-302743967.html
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
/PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between...
nektar therapeuticssecurities fraudnktrinvestorsopportunity
https://www.biospace.com/trovagene-announces-research-collaboration-with-nektar-therapeutics-to-evaluate-efficacy-of-the-combination-of-onvansertib-and-onzeald-in-models-of-colorectal-cancer
Trovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the...
May 24, 2019 - ONZEALD is currently being evaluated in a Phase 3 trial in patients with metastatic breast cancer and brain metastases
research collaborationnektar therapeutics
https://www.newsfilecorp.com/release/292622/ROSEN-A-TOP-RANKED-LAW-FIRM-Encourages-Nektar-Therapeutics-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-NKTR
ROSEN, A TOP RANKED LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before...
New York, New York--(Newsfile Corp. - April 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm,...
https://www.einpresswire.com/article/494203762/nektar-therapeutics-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that
NEKTAR THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that...
https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-completion-of-target-enrollment-in-rezolve-aa-phase-2b-clinical-trial-of-rezpegaldesleukin-in-patients-with-severe-to-very-severe-alopecia-areata-302385779.html
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of...
https://menafn.com/1111058936/NKTR-UPCOMING-DEADLINE-The-Gross-Law-Firm-Alerts-Nektar-Therapeutics-Stockholders-Of-Securities-Class-Action-Contact-The-Firm
NKTR UPCOMING DEADLINE : The Gross Law Firm Alerts Nektar Therapeutics Stockholders Of Securities...
NKTR UPCOMING DEADLINE : The Gross Law Firm Alerts Nektar Therapeutics Stockholders Of Securities Class Action - Contact The Firm. NEW YORK, May 01, 2026...
the gross law
https://menafn.com/1111068365/NKTR-Investor-Alert-Nektar-Therapeutics-Securities-Fraud-Lawsuit-Investors-With-Losses-May-Seek-To-Lead-The-Class-Action-After-Allegedly-Misrepresenting-Enrollment-Protocol-Compliance-Levi-Korsinsky
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek...
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek To Lead The Class Action After Allegedly Misrepresenting...
https://www.biospace.com/nektar-therapeutics-to-host-webcast-conference-call-for-analysts-and-amp-investors-with-expert-oncologist-panel-during-2020-society-for-immunotherapy-of-cancer-sitc-35th-annual-meeting
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist...
Nov 10, 2020 - Nektar Therapeutics announced that it will host a webcast analyst and investor conference call with a panel of oncology experts and company management on...
https://www.biospace.com/press-releases/nektar-therapeutics-announces-completion-of-target-enrollment-in-rezolve-ad-phase-2b-clinical-trial-of-rezpegaldesleukin-in-patients-with-moderate-to-severe-atopic-dermatitis
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial...
https://www.fishersci.com/us/en/custom-homes/n/nektar-therapeutics.html
Nektar Therapeutics
nektartherapeutics
https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-closing-of-373-8-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares-302752250.html
Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today...
https://www.benzinga.com/general/biotech/22/04/26815587/after-bristol-myers-cuts-ties-nektar-implements-cost-restructuring
After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring - Nektar Therapeutics...
bristol myerscutstiesnektarimplements
https://www.biospace.com/nektar-therapeutics-announces-phase-1b-data-for-novel-t-regulatory-cell-stimulator-nktr-358-ly3471851-in-patients-with-atopic-dermatitis
Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358...
https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-the-hc-wainwright-3rd-annual-autoimmune--inflammatory-disease-virtual-conference-302407356.html
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual...
https://menafn.com/1111059406/Bronstein-Gewirtz-Grossman-LLC-Urges-Nektar-Therapeutics-Investors-To-Act-Class-Action-Filed-Alleging-Investor-Harm
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors To Act: Class Action Filed...
https://www.insidermonkey.com/blog/nektar-therapeutics-nktr-among-stocks-wall-street-is-calling-bullish-amid-market-turmoil-1489382/
Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil -...
We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil.
https://www.biospace.com/nektar-therapeutics-to-host-webcast-conference-call-with-immunology-expert-for-analysts-and-amp-investors-during-2019-european-congress-of-rheumatology-eular-2019
Nektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analysts & Investors...
Jun 12, 2019 - Nektar Therapeutics announced that it will webcast an analyst and investor conference call with an immunology expert and company management on Thursday, June...
https://menafn.com/1111068356/NKTR-Investor-Alert-Nektar-Therapeutics-Securities-Fraud-Lawsuit-Investors-With-Losses-May-Seek-To-Lead-The-Class-Action-After-Allegedly-Misrepresenting-Enrollment-Protocol-Compliance-Levi-Korsinsky
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek...
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek To Lead The Class Action After Allegedly Misrepresenting...